Difference between revisions of "Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro"
Jump to navigation
Jump to search
(Created page with "Category:Article Category:Covid19 {| class="infobox" width=200px |class="publication"|'''Publication''' |- |Title || <ul>[https://www.nature.com/articles/s41421-020-01...") |
|||
| Line 23: | Line 23: | ||
== Major Issues == | == Major Issues == | ||
| − | No major issues identified. | + | No major issues identified at this time. |
== Minor Issues == | == Minor Issues == | ||
| − | No minor issues identified. | + | No minor issues identified at this time. |
== Impact == | == Impact == | ||
Latest revision as of 17:09, 22 July 2020
| Publication | |
| Title | |
| Authors |
|
| Journal | Cell Discovery |
| Date | March 18, 2020 |
In vitro study demonstrating that hydroxychloroquine is effective in inhibiting SARS-CoV-2 infection by blocking the transport of SARS-CoV-2 from EEs to Els, which is a requirement to release the viral genome. Authors conclude that hydroxychloroquine’s in vitro effect of inhibiting viral replication in combination with its anti-inflammatory function makes the drug a good candidate for treatment of COVID-19.
Major Issues
No major issues identified at this time.
Minor Issues
No minor issues identified at this time.
Impact
This study demonstrated in vitro efficacy of hydroxychloroquine in blocking a necessary step in viral replication of SARS-CoV-2.
Article Revisions
None at this time.